BioCentury | Nov 14, 2020
Management Tracks

COVID, Brexit await Cooke as she takes helm of EMA

Emer Cooke has succeeded Guido Rasi as EMA’s executive director, giving the regulatory agency its first new leader since 2011, handing the Irish national the task of navigating the agency through...
BioCentury | Oct 22, 2020
Regulation

Data byte: who’s who among members of FDA’s COVID-19 vaccines advisory panel

The 18 members of the advisory committee that will meet Thursday to discuss FDA’s criteria for emergency use authorization of COVID-19 vaccines bring a variety of expertise and priorities to the table, from statistical chops...
BioCentury | Oct 2, 2020
Finance

Next stop IPO? Olema adds to momentum with $85M series C

Two weeks after former AstraZeneca CMO Sean Bohen took over as president and CEO, Olema has raised $85 million in a series C round led by Vivo Capital. The San Francisco company’s next financing may well...
BioCentury | Sep 18, 2020
Management Tracks

Former AZ CMO Bohen brings his cancer chops to Olema

Two months after closing a $54 million series B round, breast cancer company Olema has followed up a flurry of executive hires with the addition of former AstraZeneca CMO Sean Bohen as president and CEO. ...
BioCentury | Aug 27, 2020
Translation in Brief

AbbVie, Harvard in $30M emerging infections partnership, Peel’s cancer therapy from CHOP and Stoke’s Dravet therapy

...chemoresistant tumor therapy based on SN22, a prodrug of irinotecan. In a Cancer Research paper published Monday, a CHOP...
BioCentury | May 26, 2020
Distillery Therapeutics

Targeting the super elongation complex for diffuse midline glioma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Inhibiting AFF4 and CDK9, components of the transcription-regulating super elongation complex, could treat diffuse midline glioma. In human diffuse midline glioma cell lines, shRNAs targeting AFF4 or CDK9 or...
BioCentury | Dec 5, 2019
Finance

With $75M from Apple Tree, Limelight seeks to overcome limitations of genetic therapy

...co-director of CAROT; and Phil Johnson, a former CSO of the Children’s Hospital of Philadelphia (CHOP...
BioCentury | Oct 31, 2019
Product Development

Amgen deal gives BeiGene dry powder to grow its own pipeline

In its second major -- and potentially transformational -- deal with a U.S. company, BeiGene has entered a development and commercialization deal with Amgen that adds nearly two dozen compounds to the Chinese biotech’s marketed...
BioCentury | Oct 12, 2019
Politics, Policy & Law

BIO: Two heads are better than one

The search for new leadership at BIO presents its board with generational opportunity to redefine the organization to ensure its relevance in a time of tumultuous political, technological and cultural change. The urgency for outside-the-box...
BioCentury | Oct 1, 2019
Company News

Oct. 1 Company Quick Takes: NVS, Microsoft to use AI for drug R&D; plus AstraZeneca, Tmunity-CHOP and AGTC-Otonomy deals

...primary endpoint in August; the trial had not finished when AZ submitted the NDA. Tmunity, CHOP...
...the Children's Hospital of Philadelphia to develop a GPC2-targeting CAR T therapy to treat neuroblastoma. CHOP...
Items per page:
1 - 10 of 315